Loading...
ELVN logo

Enliven Therapeutics, Inc.NasdaqGS:ELVN Stock Report

Market Cap US$3.6b
Share Price
n/a
1Y160.8%
7D-9.0%
1D-1.6%
Portfolio Value
​
View

Enliven Therapeutics, Inc.

NasdaqGS:ELVN Stock Report

Market Cap: US$3.6b

Enliven Therapeutics (ELVN) Stock Overview

A clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. More details

ELVN fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 84.45% per year

Analysts in good agreement that stock price will rise by 49.4%

Risk Analysis

Earnings are forecast to decline by an average of 16.3% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Shareholders have been diluted in the past year


ELVN Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW427,144 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
427,144 investors already sharing narratives
View all narratives

Enliven Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Enliven Therapeutics
Historical stock prices
Current Share PriceUS$49.45
52 Week HighUS$62.32
52 Week LowUS$14.79
Beta0.25
1 Month Change-16.07%
3 Month Change9.65%
1 Year Change160.81%
3 Year Change275.47%
5 Year Changen/a
Change since IPO108.21%

Recent News & Updates

Seeking Alpha • Sep 03

Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing

Summary Enliven Therapeutics is positioned as a late-stage, well-capitalized biotech with $895M cash, funding operations into 2030 and the pivotal ENABLE-2 trial. ELVN-001 targets chronic myeloid leukemia as a selective ATP-competitive inhibitor, aiming for a differentiated, chronic-use profile in a sequential treatment paradigm. Phase 1 data show 61% MMR at 80 mg daily, with favorable safety and convenience for chronic administration, supporting potential in earlier-line CML settings. ELVN’s investment case hinges on ELVN-001 becoming the preferred active-site TKI, not replacing all TKIs, with the ENABLE-2 Phase 3 trial as the near-term catalyst. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Sep 03

Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing

Summary Enliven Therapeutics is positioned as a late-stage, well-capitalized biotech with $895M cash, funding operations into 2030 and the pivotal ENABLE-2 trial. ELVN-001 targets chronic myeloid leukemia as a selective ATP-competitive inhibitor, aiming for a differentiated, chronic-use profile in a sequential treatment paradigm. Phase 1 data show 61% MMR at 80 mg daily, with favorable safety and convenience for chronic administration, supporting potential in earlier-line CML settings. ELVN’s investment case hinges on ELVN-001 becoming the preferred active-site TKI, not replacing all TKIs, with the ENABLE-2 Phase 3 trial as the near-term catalyst. Read the full article on Seeking Alpha
Analysis Article • Apr 27

We're Not Worried About Enliven Therapeutics' (NASDAQ:ELVN) Cash Burn

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Aug 15

Companies Like Enliven Therapeutics (NASDAQ:ELVN) Are In A Position To Invest In Growth

NasdaqGS:ELVN 1 Year Share Price vs Fair Value Explore Enliven Therapeutics's Fair Values from the Community and select...
Seeking Alpha • Apr 22

Enliven Therapeutics: Awaiting Additional Trial Data

Summary Today, I take my first look at Enliven Therapeutics, Inc., a clinical-stage concern that has two candidates in its pipeline targeting oncology indications. Enliven ended FY2024 with over $310 million in cash and marketable securities, with no long-term debt and funding secured until mid-2027. The analyst firm community is optimistic about the prospects for Enliven Therapeutics, but insider selling over the past year is somewhat bothersome. An analysis of Enliven Therapeutics follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Apr 01

We Think Enliven Therapeutics (NASDAQ:ELVN) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • Jan 07

Enliven's Early Data Stands Out From Peers

Summary Enliven Therapeutics' ELVN-001 shows promising interim data, achieving a 44% major molecular response rate in heavily pre-treated CML patients within 12 weeks. ELVN-001 targets the BCR-ABL gene fusion, addressing resistance issues seen with other TKIs, including the T315I mutation. Financially, Enliven has a market cap of $1.9bn and a cash runway of 7–8 quarters, supporting continued R&D efforts. Despite early-stage data risks, ELVN-001's strong profile and unmet medical need make it a speculative buy at slightly lower prices. Read the full article on Seeking Alpha
Analysis Article • Dec 14

Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Aug 29

We Think Enliven Therapeutics (NASDAQ:ELVN) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Shareholder Returns

ELVNUS PharmaceuticalsUS Market
7D-9.0%1.7%0.5%
1Y160.8%47.1%12.0%

Return vs Industry: ELVN exceeded the US Pharmaceuticals industry which returned 47.1% over the past year.

Return vs Market: ELVN exceeded the US Market which returned 12% over the past year.

Price Volatility

Is ELVN's price volatile compared to industry and market?
ELVN volatility
ELVN Average Weekly Movement5.7%
Pharmaceuticals Industry Average Movement8.4%
Market Average Movement6.8%
10% most volatile stocks in US Market15.2%
10% least volatile stocks in US Market2.9%

Stable Share Price: ELVN has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: ELVN's weekly volatility has decreased from 11% to 6% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201967Rick Fairwww.enliventherapeutics.com

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.

Enliven Therapeutics, Inc. Fundamentals Summary

How do Enliven Therapeutics's earnings and revenue compare to its market cap?
ELVN fundamental statistics
Market capUS$3.62b
Earnings (TTM)-US$105.93m
Revenue (TTM)n/a
0.0x
P/S Ratio
-34.2x
P/E Ratio

Is ELVN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ELVN income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$105.93m
Earnings-US$105.93m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-1.45
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ELVN perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/19 03:33
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Enliven Therapeutics, Inc. is covered by 16 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullBaird
Colleen KusyBaird
Etzer DaroutBarclays